COLO-B Coloplast A/S
Coloplast A/S develops and sells intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through five segments: Chronic Care, Voice & Respiratory Care, Interventional Urology, Advanced Wound Dressings, and Biologics. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; Peristeen Plus, a transanal irrigation system; and Peristeen Light, a low-volume transanal irrigation. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as erectile dysfunction, urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About Coloplast (CPH: COLO-B)
›
Coloplast (CPH: COLO-B) is listed on Nasdaq Copenhagen, where its shares trade in DKK. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 17,270 employees.
The shares were at 499.50 DKK on 19 November 2026, down 6.4% over 52 weeks. Its 52-week range is 369.70 DKK to 631.40 DKK: the price is 20.9% below the high and 35.1% above the low.
At a market capitalisation of 112.57B DKK, it trades at 36.6 times trailing earnings and 18.6 times forward earnings. The median trailing P/E of its 18 largest Medical Instruments & Supplies peers is 51.8, a discount of 29% for COLO-B. It pays a dividend yielding 4.58% (it pays out 169% of its earnings), against a median of 0.71% among the dividend payers in that peer group.
Coloplast reports return on equity of 21.5%, an operating margin of 25.7% and revenue up 7.2% year over year.
Its debt exceeds its cash by 21.01B DKK, a debt-to-equity ratio of 1.51. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 21 analysts cover the stock, with an average rating of Hold; their mean price target of 473.81 DKK is 5.1% below the current price. The next earnings report is expected on 9 February 2027.